FranΓ§ais| Metric | AbbVie | Johnson & Johnson | Edge |
|---|---|---|---|
| Price | $291 | $275 | |
| Median target (12m) | $290 (-0%) | $287 (+4%) | |
| Analyst reliability (1y) | 52% | 26% | π’ ABBV |
| Avg gain / call (1y) | +15% | +11% | |
| P/E | 82.1 | 41.8 | π΅ JNJ |
| $1000 invested (10y ago) | $4,248 | $2,472 | π’ ABBV |
| Year | ABBV | JNJ | Winner |
|---|---|---|---|
| 2026 | +10% | +23% | π΅ JNJ |
| 2025 | +29% | +43% | π΅ JNJ |
| 2024 | +15% | -8% | π’ ABBV |
| 2023 | -4% | -11% | π’ ABBV |
| 2022 | +19% | +3% | π’ ABBV |
| 2021 | +26% | +9% | π’ ABBV |
| 2020 | +21% | +8% | π’ ABBV |
| 2019 | -4% | +13% | π΅ JNJ |
| 2018 | -5% | -8% | π’ ABBV |
| 2017 | +54% | +21% | π’ ABBV |
| 2016 | +6% | +12% | π΅ JNJ |
Over ~10 years, AbbVie returned $4,248 on $1000 vs $2,472 for Johnson & Johnson, and AbbVie has better analyst reliability. Not advice: also check valuation (P/E) and your horizon.
Over ~10 years, AbbVie wins ($4,248 vs $2,472 on $1000 invested, price return excluding dividends).
On P/E, Johnson & Johnson is cheaper (82.1 vs 41.8). A lower P/E isn't always a better deal (growth matters).
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Past price performance (excluding dividends). Data: Yahoo Finance.